侯宁，广州医科大学博士学位，药理学教授，博士生导师，广东省优秀青年教师培养对象，广州市高层次人才-青年后备人才，广东省“千百十计划”校级培养对象，广州医科大学南山学者后备人才，广州医科大学高水平大学学术骨干培育对象。中国心血管药理专业委员会委员，中国药理学会心血管药理专业委员会青年委员会委员，广东省药理学会药理教育专业委员会委员，广东省药理学会炎症免疫专业委员会委员。

近年来主持国家级科研项目2项，省市级科研项目6项，获得经费资助100余万。授权国家专利3项，申请专利4项（排名第一）。在Circulation-Heart Failure、Archives of Toxicology、Cardiovascular Research等杂志发表SCI论文多篇，Frontiers in Pharmacology杂志特约编辑，International Journal of Biological Science、Drug design, development and therapy等杂志专任审稿人。

【联系邮箱】

houning-2003@163.com

【研究方向】

糖尿病心血管疾病的发病机制及防治

【主要科研项目】

1. 国家自然科学基金面上项目，81773720，《转录共激活因子Yap/Taz活化导致糖尿病心肌损伤的分子机制研究》，2018/01-2020/12, 经费53万，在研，主持

2. 国家自然科学基金青年项目，81402928，《高糖激活的wnt/β-catenin/TCF7L2信号通路诱导糖尿病心肌能量代谢紊乱的作用及机制》，2015/01-2017/12, 经费24万，结题，主持。

3. 广东省自然科学基金面上项目，2019A1515011848，《细胞内HO-1途径代谢产物胆红素在心肌肥厚中的作用》，2019/10/1-2022/09/30，经费10万，在研，主持。

4. 广州市科技计划项目，201804010490，《转录共活化因子Yap/Taz在糖尿病心肌病中的作用及分子机制研究》，2018/04-2021/03，经费20万，在研，主持

5. 广州市教育科研计划项目，1201610064，《染色质重组复合物核心亚单位Brg1在糖尿病心肌损伤中的保护作用及机制研究》，2017/01-2018/12, 经费8万，结题，主持。

6. 广东省教育厅普通高校特色创新项目，2016KTSCX114，《染色质重组复合物在糖尿病心功能障碍中的作用及机制初探》，2017/01-2019/12，20万，结题，主持。

7. 广东省教育厅高等学校优秀青年教师培养计划，YQ2015135，《Sonic Hedgehog信号通路受损对糖尿病心肌梗死DNA损伤及其修复的影响和调控机制》，2016/01-2018/12, 经费30万，结题，主持。

【主要论文及著作（代表性）】

1. Xiaoping Liu, XunYuan, GuanfengLiang, Shuyun Zhang, Guiping Zhang, Yuan Qin, Qiulian Zhu, Qing Xiao, Ning Hou, Jian-dong Luo. BRG1 protects the heart from acute myocardial infarction by reducing oxidative damage through the activation of the NRF2/HO1 signaling pathway. Free Radical Biology and Medicine. 2020, Nov,160(20):820-836. （通讯作者）

2. Hongqi Chen, Wenliang Chen, Yinlian Yao, Naobei Ye, Ning Hou, Jiandong Luo. Upregulation of CFTR Protects against Palmitate-induced Endothelial Dysfunction by Enhancing Autophagic Flux. Oxidative Medicine and Cellular Longevity. 2020 Oct 17; 2020: 8345246. （通讯作者）

3. Xiaoqing Chen^#, Wenchang Yuan^#, Yilang Li , Jiandong Luo^{1, *}, Ning Hou^*. Role of Hippo-YAP1/TAZ pathway and its crosstalk in cardiac biology. International journal of biological sciences. Int J Biol Sci 2020; 16(13):2454-2463. （通讯作者）

4. Yilang Li, Yunpei Mai, Xiaoxia Qiu, Xiaoqing Chen, Conglin Li, Wenchang Yuan, Ning Hou(通讯作者). Effect of Long-Term Treatment of Carvacrol on Glucose Metabolism in Streptozotocin-induced Diabetic Mice. BMC-Complement Med Ther, 2020, 20(142). （通讯作者）

5. Xiaoqing Chen, Yilang Li , Jiandong Luo , Ning Hou. Molecular mechanism of Hippo–YAP1/TAZ pathway in heart development, disease, and regeneration. Front. Physiol, 2020, 11:389. （通讯作者）

6. Ning Hou, Yin Huang, Shao-Ai Cai, Wen-Chang Yuan, Li-Rong Li, Xia-Wen Liu, Gan-Jian Zhao, Xiao-Xia Qiu, Ai-Qun Li, Chuan-Fang Cheng, Shi-Ming Liu, Xiao-Hui Chen, Dao-Feng Cai, Jing-Xuan Xie, Min-Sheng Chen, Cheng-Feng Luo. Puerarin Ameliorated Pressure Overload-induced Cardiac Hypertrophy in Ovariectomized Rats Through Activation of the PPARα/PGC-1 pathway. Acta Pharmacologica Sinica, 2021 Jan;42(1):55-67.  

7. Yun Liu, Jie Wei, Kai-Ting M, Cong-Lin Li, Yun-Pei Mai, Xiao-Xia Qiu, Han Wei, Ning Hou(共同通讯), Jian-Dong Luo. Carvacrol protects against diabetes-induced hypercontractility in the aorta through activation of the PI3K/Akt pathway. Biomedicine & Pharmacotherapy. 2020 May;125:109825.

8. Hou N, Mai Y, Qiu X, Yuan W, Li Y, Luo C, Liu Y, Zhang G, Zhao G and Luo J-d. Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice. Front. Pharmacol. 2019,10:998.

9. Sun N, Li D, Chen X, Wu P, Lu YJ, Hou N(共同通讯), Chen WH, Wong WL. New applications of oleanolic acid and its derivatives as cardioprotective agents: A review of their therapeutic perspectives. Curr Pharm Des. 2019, Nov 4, 23(35):3740-3750.

10. Wenchang Yuan, Jianhua Liu, Youchao Zhan, Li Wang, Yanqiong Jiang, Yanling Zhang, Ning Sun, Ning Hou. Molecular typing revealed the emergence of pvl-positive sequence type 22 methicillin-susceptible Staphylococcus aureus in Urumqi, Northwestern China. Infection and Drug Resistance, 2019 June 20 2019;12:1719-1728. (通讯作者)

11. Cai SA#, Hou N#, Zhao GJ, Liu XW, He YY, Liu HL, Hua YQ, Li LR, Huang Y, Ou CW, Luo CF, Chen MS. Nrf2 Is a Key Regulator on Puerarin Preventing Cardiac Fibrosis and Upregulating Metabolic Enzymes UGT1A1 in Rats. Front Pharmacol. 2018 Jun 6;9:540. （共同第一作者）

12. Zhao G#, Hou N#, Cai SA, Liu XW, Li AQ, Cheng CF, Huang Y, Li LR, Mai YP, Liu SM, Ou CW, Xiong ZY, Chen XH, Luo CF, Chen MS. Contributions of Nrf2 to Puerarin Prevention of Cardiac Hypertrophy and its Metabolic Enzymes Expression in Rats. J Pharmacol Exp Ther. 2018 Sep;366(3):458-469. （共同第一作者）

13. Hou N, Wen Y, Yuan X, Xu H, Wang X, Li F*, Ye B*. Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy. Exp Mol Pathol. 2017, 103(3):267-275.

14. Hou N#, Cai B#, Ou CW#, Zhang ZH, Liu XW, Yuan M, Zhao GJ, Liu SM, Xiong LG, Luo JD, Luo CF* and Chen MS*. Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2017, 390(5):535–545.

15. Hou N#, Ye B#, Li X, Margulies KB, Xu H, Wang X and Li F*. Transcription Factor 7-like 2 Mediates Canonical Wnt/beta-Catenin Signaling and c-Myc Upregulation in Heart Failure. Circ Heart Fail. 2016; 9(6): e003010.